A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus by Treiman, David M., , M.D. et al.
Virginia Commonwealth University
VCU Scholars Compass
VCU Medical Center Publications VCU Medical Center
1998
A Comparison of Four Treatments for Generalized
Convulsive Status Epilepticus
David M. Treiman , M.D.
Veterans Affairs Medical Centers in West Los Angeles
Patti D. Meyers , M.P.A.
Veterans Affairs Medical Centers in West Los Angeles
Nancy Y. Walton , Ph.D.
Veterans Affairs Medical Centers in West Los Angeles
See next page for additional authors
Follow this and additional works at: http://scholarscompass.vcu.edu/vcuhealth_pubs
Part of the Medicine and Health Sciences Commons
From The New England Journal of Medicine, Treiman, D.M., Meyers, P.D., Walton, N.Y., et al., A Comparison of Four
Treatments for Generalized Convulsive Status Epilepticus, Vol. 339, Page 792, Copyright © 1998 Massachusetts Medical
Society. Reprinted with permission.
This Article is brought to you for free and open access by the VCU Medical Center at VCU Scholars Compass. It has been accepted for inclusion in
VCU Medical Center Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/vcuhealth_pubs/18
Authors
David M. Treiman , M.D.; Patti D. Meyers , M.P.A.; Nancy Y. Walton , Ph.D.; Joseph F. Collins , Sc.D.; Cindy
Colling , R.Ph., M.S.; A. James Rowan , M.D.; Adrian Handforth , M.D.; Edward Faught , M.D.; Vincent P.
Calabrese , M.D.; Basim M. Uthman , M.D.; R. Eugene Ramsay , M.D.; Meenal B. Mamdani , M.D.; Pratap
Yagnik , M.D.; John C. Jones , M.D.; Elizabeth Barry , M.D.; Jane G. Boggs , M.D.; and Andres M. Kanner ,
M.D.
This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/vcuhealth_pubs/18
 792
 
·
 
September 17, 1998
 
The New England Journal  of  Medicine
 
A COMPARISON OF FOUR TREATMENTS FOR GENERALIZED CONVULSIVE 
STATUS EPILEPTICUS
 
D
 
AVID
 
 M. T
 
REIMAN
 
, M.D., P
 
ATTI
 
 D. M
 
EYERS
 
, M.P.A., N
 
ANCY
 
 Y. W
 
ALTON
 
, P
 
H
 
.D., J
 
OSEPH
 
 F. C
 
OLLINS
 
, S
 
C
 
.D., 
C
 
INDY
 
 C
 
OLLING
 
, R.P
 
H
 
., M.S., A. J
 
AMES
 
 R
 
OWAN
 
, M.D., A
 
DRIAN
 
 H
 
ANDFORTH
 
, M.D., E
 
DWARD
 
 F
 
AUGHT
 
, M.D., 
V
 
INCENT
 
 P. C
 
ALABRESE
 
, M.D., B
 
ASIM
 
 M. U
 
THMAN
 
, M.D., R. E
 
UGENE
 
 R
 
AMSAY
 
, M.D., 
 
AND
 
 M
 
EENAL
 
 B. M
 
AMDANI
 
, M.D., 
 
FOR
 
 
 
THE
 
 V
 
ETERANS
 
 A
 
FFAIRS
 
 S
 
TATUS
 
 E
 
PILEPTICUS
 
 C
 
OOPERATIVE
 
 S
 
TUDY
 
 G
 
ROUP
 
*
 
A
 
BSTRACT
 
Background and Methods
 
Although generalized
convulsive status epilepticus is a life-threatening
emergency, the best initial drug treatment is uncer-
tain. We conducted a five-year randomized, double-
blind, multicenter trial of four intravenous regimens:
diazepam (0.15 mg per kilogram of body weight) fol-
lowed by phenytoin (18 mg per kilogram), lorazepam
(0.1 mg per kilogram), phenobarbital (15 mg per kil-
ogram), and phenytoin (18 mg per kilogram). Pa-
tients were classified as having either overt general-
ized status epilepticus (defined as easily visible
generalized convulsions) or subtle status epilepticus
(indicated by coma and ictal discharges on the elec-
troencephalogram, with or without subtle convulsive
movements such as rhythmic muscle twitches or
tonic eye deviation). Treatment was considered suc-
cessful when all motor and electroencephalographic
seizure activity ceased within 20 minutes after the
beginning of the drug infusion and there was no re-
turn of seizure activity during the next 40 minutes.
Analyses were performed with data on only the 518
patients with verified generalized convulsive status
epilepticus as well as with data on all 570 patients
who were enrolled.
 
Results
 
Three hundred eighty-four patients had a
verified diagnosis of overt generalized convulsive sta-
tus epilepticus. In this group, lorazepam was suc-
cessful in 64.9 percent of those assigned to receive it,
phenobarbital in 58.2 percent, diazepam and pheny-
toin in 55.8 percent, and phenytoin in 43.6 percent
(P=0.02 for the overall comparison among the four
groups). Lorazepam was significantly superior to
phenytoin in a pairwise comparison (P=0.002).
Among the 134 patients with a verified diagnosis of
subtle generalized convulsive status epilepticus, no
significant differences among the treatments were
detected (range of success rates, 7.7 to 24.2 per-
cent). In an intention-to-treat analysis, the differenc-
es among treatment groups were not significant, ei-
ther among the patients with overt status epilepticus
(P=0.12) or among those with subtle status epilepti-
cus (P=0.91). There were no differences among the
treatments with respect to recurrence during the 12-
hour study period, the incidence of adverse reac-
tions, or the outcome at 30 days. 
 
Conclusions
 
As initial intravenous treatment for
overt generalized convulsive status epilepticus, lora-
zepam is more effective than phenytoin. Although
lorazepam is no more efficacious than phenobarbital
or diazepam and phenytoin, it is easier to use. (N Engl
J Med 1998;339:792-8.)
 
©1998, Massachusetts Medical Society.
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TATUS epilepticus is a life-threatening emer-
gency that affects 65,000
 
1
 
 to 150,000
 
2
 
 peo-
ple in the United States each year. General-
ized convulsive status epilepticus is the most
common and most dangerous type. 
Phenobarbital,
 
3-5
 
 phenytoin,
 
6-14
 
 diazepam plus phen-
ytoin,
 
15,16
 
 and lorazepam
 
17-28
 
 have been advocated for
the initial treatment of generalized convulsive status
epilepticus, and each is used by a substantial number
of physicians.
 
3
 
 There are few data from controlled
trials, however, to document the efficacy of these
treatments, and they have not been directly com-
pared. We therefore undertook this study to com-
pare the efficacy of standard doses of these four drugs
in the treatment of generalized convulsive status ep-
ilepticus.
 
METHODS
 
Study Design
 
In a double-blind study conducted at 16 Veterans Affairs med-
ical centers and 6 affiliated university hospitals between July 1,
1990, and June 30, 1995, patients with generalized convulsive
status epilepticus were randomly assigned to receive intravenous
S
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treatment with lorazepam, phenobarbital, phenytoin, or diaz-
epam followed by phenytoin. 
Overt generalized convulsive status epilepticus was defined as
recurrent convulsions without complete recovery between sei-
zures, and subtle generalized convulsive status epilepticus as the
stage of generalized convulsive status when the patient is in con-
tinuous coma but only subtle motor convulsions are seen.
 
29
 
 Pa-
tients were classified as having one of these two types of status ep-
ilepticus according to the following operational definitions. Overt
generalized convulsive status epilepticus was considered present
when there were two or more generalized convulsions, without
full recovery of consciousness between seizures, or continuous
convulsive activity for more than 10 minutes (treatment after 10
minutes of continuous seizure activity was considered essential to
protect against neuronal and systemic damage from ongoing sei-
zure activity). Subtle generalized convulsive status epilepticus was
considered present when the patient had coma and ictal discharges
on the electroencephalogram,
 
30
 
 with or without subtle convulsive
movements (rhythmic twitching of the arms, legs, trunk, or facial
muscles; tonic eye deviation; or nystagmoid eye jerking). If the in-
vestigator required an electroencephalogram to diagnose general-
ized convulsive status epilepticus, the patient was considered to
have subtle generalized convulsive status epilepticus.
The key criterion for study entry was evidence of overt or subtle
generalized convulsive status epilepticus at the time of evaluation,
regardless of prior drug treatment. Patients who had received
treatment and whose seizures had stopped were not eligible for in-
clusion. Other exclusion criteria included status epilepticus of a
type other than generalized convulsive, an age of less than 18
years, pregnancy, a neurologic emergency requiring immediate
surgical intervention, and the presence of a specific contraindica-
tion to therapy with hydantoin, benzodiazepine, or barbiturate
drugs. If patients with repeated episodes of generalized convulsive
status epilepticus were inadvertently enrolled more than once,
only the first episode was included in the analysis.
A blood sample was obtained before treatment for hematologic
and serum-chemistry tests and for screening for antiepileptic
drugs. Intravenous access was established with normal saline. The
order of the treatments was determined by random assignment.
Separate randomization schemes were used at each site for each
type of status epilepticus. Treatment kits were placed at three or
four locations within each participating center, and for each pa-
tient the lowest-numbered kit at the location nearest to the pa-
tients was used. Electroencephalographic recording was started as
soon as possible after the initiation of the protocol, but treatment
was never delayed until the electroencephalogram could be ob-
tained unless it was necessary to confirm the diagnosis. Blood
pressure, heart rate, respiratory rate, level of consciousness, and
seizure activity were recorded every 5 minutes for the first 20
minutes after the drug infusion began and then every 10 minutes
for the next 40 minutes. Seizure activity and level of conscious-
ness were recorded every hour thereafter until the completion of
the 12-hour study period. Blood was obtained before the initial
infusion, at the completion of the infusion, and 2 hours and 12
hours after the start of the infusion for the measurement of anti-
convulsant-drug concentrations.
Treatment was considered successful if all clinical and electrical
evidence of seizure activity stopped within 20 minutes after the
start of the infusion and did not recur during the period from 20
to 60 minutes after the start of treatment. Electrical seizure ac-
tivity included any of the five ictal patterns described previously.
 
30
 
 
 
Informed Consent
 
From the institutional review board at each participating hos-
pital, we obtained approval for the study and permission to waive
the requirement for informed consent until after the initial ran-
domized treatment. The rationale for the waiver was that the four
study treatments were the four best treatments then available, and
the patient was assumed to want the best available treatment. Be-
cause there were insufficient data to guide the selection of one
treatment over another, any of the four treatments could be con-
sidered the best. Informed consent for continued participation in
the study was obtained from the patient or a family member or
other surrogate after initial treatment. Most patients were not
competent to give informed consent during the 12-hour study
period; some never recovered sufficiently to be able to provide
consent. In such cases, consent was obtained from a surrogate, if
one was available. State laws and institutional review board regu-
lations regarding surrogate consent were adhered to at all sites.
Consent was written, unless oral consent was permitted by a spe-
cific institution.
 
Drug Treatment
 
Phenytoin (Dilantin, Parke-Davis, Morris Plains, N.J.), pheno-
barbital (Spectrum Chemical, Gardena, Calif.), and diazepam
 
*To convert drug concentrations to millimoles per liter, multiply by the following: lorazepam, 3.11;
phenobarbital, 4.31; diazepam, 3.51; and phenytoin, 3.96.
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P
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Dose (mg/kg) 0.1 15 0.15 and 18 18
Maximal rate of administration 
(mg/min)
2 100 5 and 50 50
Drug-solution concentration 
(mg/ml)
 
*
 
4 100 5 and 50 50
Contents of first treatment box
Tubex
Vial A
Vial B
Vial C
Vial D
Vial E
Lorazepam
Dummy
Dummy
Dummy
Dummy
Dummy
Dummy
Phenobarbital
Phenobarbital
Phenobarbital
Dummy
Dummy
Dummy
Diazepam
Phenytoin
Phenytoin
Phenytoin
Phenytoin
Dummy 
Phenytoin
Phenytoin
Phenytoin
Phenytoin
Dummy
Active drug in second treatment box Phenytoin Phenytoin Lorazepam Lorazepam
Active drug in third treatment box Phenobarbital Lorazepam Phenobarbital Phenobarbital
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(Valium, Hoffmann–LaRoche, Nutley, N.J.) were packaged in
identical vials at appropriate concentrations so each of the drugs
could be administered at a rate of 1 ml per minute to produce the
maximal rates of drug infusion shown in Table 1. Lorazepam (Ati-
van, Wyeth–Ayerst, Philadelphia) was administered by means of
Tubex injection at a maximal rate of 0.5 ml per minute.
Identical-appearing drug-treatment kits were prepared for each
drug regimen, with each kit containing a first, a second, and a
third treatment box. The first treatment box consisted of one
Tubex syringe and five vials, labeled A through E. A nomogram,
based on the patient’s weight, was used to determine the volume
of solution administered from the Tubex and from each vial to
produce the desired dose without compromising the blinded na-
ture of the study. The Tubex solution and the solution from vial
A were injected simultaneously. Tubexes and vials with active
drug contained propylene glycol, as did dummy Tubexes; dummy
vials contained normal saline. The second and third treatment
boxes were provided to allow subsequent treatment, if necessary,
without revealing the identity of the study drug. Active drugs in
the second and third boxes for each treatment regimen are listed
in Table 1. 
 
Central Review
 
We used a central procedure for review of electroencepha-
lograms and data verification to ensure consistency among the
hospitals in the diagnosis and classification of generalized convul-
sive status epilepticus and the determination of treatment success.
A committee consisting of the study chairman, project director,
and electroencephalographer reviewed all clinical data and elec-
troencephalographic recordings obtained during the 12-hour
study period. Differences of opinion between the central com-
mittee and investigators at the study sites were resolved by discus-
sion. The review committee remained blinded to the identity of
the treatment drug in each case until the review of all cases was
completed.
 
Statistical Analysis
 
The study was designed to analyze the patients with overt and
subtle generalized convulsive status epilepticus separately, because
we anticipated a significant difference in outcome in the two
groups. Analyses were performed both on an intention-to-treat
basis, with all enrolled patients included, and with only patients
included who had a verified diagnosis of generalized convulsive
status epilepticus. The intention-to-treat analyses included pa-
tients who were mistakenly assigned to the wrong status group
(e.g., overt instead of subtle status epilepticus), had other types
of status epilepticus, or did not actually have status epilepticus. In
the intention-to-treat analysis, patients in the last group were clas-
sified as having been successfully treated. For the analyses restrict-
ed to patients with verified diagnoses, patients were assigned to
their correct status group (overt or subtle), as determined by the
central review. Patients who did not have generalized convulsive
status epilepticus were excluded from the verified-diagnosis analy-
ses. Chi-square techniques were used to analyze rates of treat-
ment success, recurrence, and adverse events. The alpha level was
set at 0.05 for analyses of all four treatments, and a two-tailed al-
pha level of 0.01 was used to determine the significance of differ-
ences between any two regimens.
 
31
 
 Cochran–Mantel–Haenszel
statistics
 
32
 
 were used for the post hoc combined status-group
analyses.
 
RESULTS
 
We attempted to enroll all eligible patients at each
participating hospital. We screened 1705 patients
during the study period; 570 were enrolled (395
with overt status epilepticus and 175 with subtle sta-
tus epilepticus). Of the 1135 who were not enrolled,
113 were eligible but were not included because the
study team was not called. The other 1022 were ex-
cluded for one or more of the following reasons: ab-
sence of generalized convulsive status epilepticus
(868 patients), previous enrollment in the study (41),
contraindication to phenytoin therapy (48), con-
traindication to barbiturate therapy (21), contraindi-
cation to benzodiazepine therapy (13), age of less
than 18 years (1), pregnancy (1), presence of a neu-
rosurgical emergency (20), and other reasons (236).
Fifty-two of the 570 enrolled patients did not have
generalized convulsive status epilepticus at the time
of randomization. In addition, 18 patients classified
as having subtle status epilepticus at randomization
actually had overt generalized convulsive status epi-
lepticus. As a result, 384 patients with verified overt
status epilepticus and 134 with subtle status epilep-
ticus (total, 518) were included in all the analyses
performed in the verified-diagnosis group; all 570
enrolled patients were included in the intention-to-
treat analysis. Data on efficacy could not be ob-
tained for five patients with overt status epilepticus. 
Table 2 summarizes the characteristics of the pa-
tients with verified diagnoses. Although there were
no significant differences among the four drug-treat-
ment groups in any of the characteristics we exam-
ined (data not shown), patients with overt and sub-
tle status epilepticus differed significantly with respect
to age, race, current use of anticonvulsants, history
of seizures, cause of status epilepticus, functional
status before the current episode, whether or not
they were veterans, the part of the hospital where
treatment took place (emergency room, ward, or in-
 
*Plus–minus values are means ±SD.
†Some patients had more than one causal factor.
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.*
 
C
 
HARACTERISTIC
 
O
 
VERT
 
 
(N=384)
S
 
UBTLE
 
(N=134)
 
Age (yr) 58.6±15.6 62.0±15.1
Veteran (%) 70.1 80.6
Male sex (%) 82.3 85.1
Not previously treated for current episode (%) 51.3 51.5
History of acute seizures (%) 54.2 25.4
History of epilepsy (%) 42.4 12.7
History of status epilepticus (%) 12.8 4.5
Median duration of status epilepticus at 
enrollment (hr)
2.8 5.8
Causal factors (%)†
Remote neurologic cause 
Acute neurologic cause 
Life-threatening medical condition 
Cardiopulmonary arrest 
Toxic effects of therapeutic or recreational 
drug 
Alcohol withdrawal 
69.5
27.3
32.0
6.3
6.3
6.5
34.3
37.3
56.7
38.1
5.2
0.7
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 21, 2015. For personal use only. No other uses without permission. 
 Copyright © 1998 Massachusetts Medical Society. All rights reserved. 
 A COMPARISON OF FOUR TREATMENTS FOR GENERALIZED CONVULSIVE STATUS EPILEPTICUS
 
Volume 339 Number 12
 
·
 
795
 
tensive care unit), history of status epilepticus, histo-
ry of excessive alcohol use, and duration of status ep-
ilepticus. 
Table 3 gives the mean doses, serum concentra-
tions after infusion, and length of time necessary to
complete infusion for each of the four initial treat-
ments. Lorazepam required the least time to infuse
(P<0.001 in paired comparisons); the treatments
that included phenytoin took the longest (P<0.001).
Figure 1 presents the results of the four treatment
regimens with respect to efficacy. In the analysis of
the 518 patients with verified diagnoses (Fig. 1A),
the first treatment regimen was successful in 55.5
percent of patients with overt status epilepticus, but
in only 14.9 percent of those with subtle status epi-
lepticus. Among the patients with overt status epi-
lepticus, chi-square analysis showed a significant dif-
ference overall (P=0.02) in the frequency of success
among the four treatments, but no differences were
detected in the group with subtle status epilepticus
(P=0.18). Lorazepam was effective significantly more
often than phenytoin (P=0.002) in patients with
overt status epilepticus. Other pairwise comparisons
did not show significant differences between individ-
ual treatments.
When the two groups were combined in a post
hoc analysis, lorazepam was successful as the first
treatment in 52.2 percent of the patients to whom
it was administered, phenobarbital in 49.2 percent,
diazepam followed by phenytoin in 43.1 percent,
and phenytoin alone in 36.8 percent. Chi-square
analysis revealed a significant difference (P=0.008)
in the frequency of success among treatments. In
paired comparisons, lorazepam was effective more
often than phenytoin (P=0.001). The difference in
efficacy between phenobarbital and phenytoin ap-
proached significance (P=0.02). The results of the
intention-to-treat analysis (Fig. 1B) were similar, but
 
*Values are means ±SD. To convert concentrations to micromoles per
liter, multiply by the following: lorazepam, 3.11; phenobarbital, 4.31; di-
azepam, 3.51; and phenytoin, 3.96.
†P<0.001 for the differences among the drug regimens.
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mg/kg µg/ml min
Lorazepam 0.10±0.01 0.231±0.299 4.7±7.2
Phenobarbital 14.96±2.53 31.2±37.2 16.6±11.5
Diazepam and phenytoin 0.15±0.02 
and
15.08±4.84
0.245±0.307
and
31.8±19.2
42.0±38.1
Phenytoin 16.02±3.21 30.0±13.6 33.0±20.1
Figure 1. Rate of Successful Initial Treatment with Each of the
Four Regimens.
Open bars indicate patients with overt generalized convulsive
status epilepticus, and solid bars those with subtle status epi-
lepticus. Panel A shows the results of our analysis of patients
with a verified diagnosis of generalized convulsive status epi-
lepticus. Among the patients with overt status epilepticus, dif-
ferences in the frequency of success among the treatments
were significant (P=0.02); in pairwise comparisons, lorazepam
was effective significantly more often than phenytoin (P=0.002).
Panel B shows the results of the intention-to-treat analysis. The
differences in the frequency of success among the treatment
groups were not significant. The success rate for each treat-
ment is indicated above the bars. 
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differences between groups were not significant for
either the patients with overt status epilepticus (P=
0.12) or those with subtle status epilepticus (P=
0.91). In the verified-diagnosis analysis, status epi-
lepticus recurred during the 12-hour study period in
11 percent (24 of 213) of patients with successfully
treated overt status epilepticus and 20 percent (4 of
20) of successfully treated patients with subtle cases.
There were no significant differences in the rates of
recurrence among the four treatments for either the
patients with a verified diagnosis of overt general-
ized convulsive status epilepticus or those with veri-
fied subtle status epilepticus.
The commonly reported side effects of treatment
are shown in Table 4. There were no significant dif-
ferences among the four treatments in either group
(those with overt or subtle generalized convulsive
status epilepticus). However, hypotension requiring
treatment occurred more often in the patients with
subtle status epilepticus than in those with overt
status epilepticus (P<0.001). Sixty-seven of the pa-
tients with overt status epilepticus (17 percent) re-
gained full consciousness before the end of the 12-
hour study period, with no significant differences
among the four treatment groups (P=0.59). None
of the patients with subtle status epilepticus com-
pletely regained consciousness during the 12-hour
study period. 
Outcomes 30 days after treatment were signifi-
cantly worse (P<0.001) for patients with subtle sta-
tus epilepticus. At 30 days, 50.1 percent of patients
with overt status epilepticus had been discharged
from the hospital, as compared with 8.8 percent of
patients with subtle status epilepticus; 22.9 percent
of those with overt status epilepticus were still in the
hospital, as compared with 26.5 percent of those
with subtle status epilepticus; mortality rates were
27.0 percent and 64.7 percent, respectively. There
were no significant differences in outcome at 30 days
among the four treatments for either the patients
with overt status epilepticus or those with subtle sta-
tus epilepticus. In both the overt and subtle status
epilepticus groups, however, patients successfully treat-
ed with the first study drug had a better prognosis
than did those in whom the first treatment was not
successful (for patients with overt status epilepticus,
P<0.001; for those with subtle status epilepticus,
P=0.01). Among patients with overt and subtle sta-
tus epilepticus, mortality was twice as high for pa-
tients whose status was not controlled with the first
drug as for those in whom the first treatment was
successful. No other follow-up data were collected.
DISCUSSION
Our results show that lorazepam is more likely
than phenytoin to be successful when used as the
initial intravenous treatment for overt generalized
convulsive status epilepticus. Although this study was
sponsored by the Department of Veterans Affairs, 30
percent of the patients with overt status epilepticus
were not veterans, and 18 percent were female, sug-
gesting that our results are widely applicable to the
treatment of generalized convulsive status epilepti-
cus in adults.
The lower overall efficacy rates reported here, as
compared with data from earlier studies,10-14,16-26 prob-
ably result from our including only patients with
generalized convulsive status epilepticus and our use
of a stringent definition of treatment success: cessa-
tion of all clinical and electrical evidence of seizure
activity within 20 minutes, with no recurrence dur-
ing the next 40 minutes. The use of a period longer
than 20 minutes in the definition of treatment suc-
cess was discussed during the development of this
protocol, but it was rejected as exposing patients to
unnecessary risk. It is desirable that medications for
this condition be given in a short intravenous infu-
sion and enter the brain rapidly during infusion.
Lorazepam, the most effective drug in the paired
comparisons, required the least time to administer.
It could be argued that the 20-minute time limit
constituted a disadvantage for phenytoin, because of
its mandatory slow infusion rate. On the other hand,
phenobarbital, which enters the brain slowly,33 was
not significantly less effective than lorazepam in
patients with overt generalized convulsive status ep-
ilepticus. Thus, it appears that the 20-minute crite-
rion for success does not in itself explain the differ-
ences we found.
We found no differences among the treatments in
the frequency of recurrence of overt or subtle status
epilepticus during the 12-hour study period, sug-
gesting that any of the four treatments, if successful,
can protect equally well against recurrence. We also
found no differences among the treatments in the
TABLE 4. FREQUENCY OF COMMON DRUG-RELATED SIDE EFFECTS 
AMONG THE 518 PATIENTS WITH VERIFIED DIAGNOSES.
TYPE OF 
GENERALIZED 
CONVULSIVE 
STATUS EPILEPTICUS 
AND SIDE EFFECT LORAZEPAM PHENOBARBITAL
DIAZEPAM 
AND 
PHENYTOIN PHENYTOIN
Overt
No. of patients 97 91 95 101
Hypoventilation (%) 10.3 13.2 16.8 9.9
Hypotension (%) 25.8 34.1 31.6 27.0
Cardiac-rhythm 
disturbance (%)
7.2 3.3 2.1 6.9
Subtle
No. of patients 39 33 36 26
Hypoventilation (%) 12.8 15.2 2.9 7.7
Hypotension (%) 59.0 48.5 58.3 57.7
Cardiac-rhythm 
disturbance (%)
7.7 9.1 5.6 0.0
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incidence of hypotension requiring treatment, respi-
ratory depression, or cardiac-rhythm disturbances in
patients with either overt or subtle generalized con-
vulsive status epilepticus. Thus, the risk of these ad-
verse events appears similar with any of the four reg-
imens if the drugs are administered at a safe rate to
patients who have been appropriately screened for
contraindications. Hypotension requiring treatment
occurred more often in the patients with subtle gen-
eralized convulsive status epilepticus; this difference
probably reflects the fact that patients with subtle
status epilepticus were sicker than those with overt
status epilepticus. Life-threatening medical condi-
tions and cardiopulmonary arrest associated with
generalized convulsive status epilepticus were more
common among the patients with subtle status epi-
lepticus (Table 2). The longer duration of status ep-
ilepticus in the patients with subtle cases (Table 2)
may also have contributed to their greater suscepti-
bility to drug-induced hypotension. Even patients
with overt status epilepticus had a long delay be-
tween onset and treatment. Many of these episodes
occurred at night, and paramedics were not called
until after several seizures had occurred. For such
patients, we considered status epilepticus to have be-
gun at the time of the first seizure.
The rapidity of recovery of consciousness after
treatment of status epilepticus is another clinically
important factor when choosing a treatment regi-
men. The small number of patients who recovered
fully within 12 hours suggests, however, that rapid,
complete recovery may not be a realistic goal when
treating generalized convulsive status epilepticus.
The condition causing the episode and the effects of
repetitive seizure activity also contribute to the im-
pairment of consciousness. Identifying significant
differences in the rates at which patients recover
from drug-induced impairment of consciousness is
difficult, because such a comparison would have to
be made in a group of patients in whom the causa-
tive factors and duration and intensity of seizures
before treatment were identical.
Overall, the patients with subtle generalized con-
vulsive status epilepticus did much worse than those
with overt generalized convulsive status epilepticus.
The first drug treatment was successful in less than
15 percent of the patients with subtle status epilep-
ticus, and their outcome was poor. Sixty-five percent
of the patients with subtle status epilepticus died
within 30 days after the episode, as compared with
27 percent of the patients with overt status epilepti-
cus. Death in a patient with generalized convulsive
status epilepticus is probably attributable largely to
the underlying cause and duration of the episode.
Nonetheless, successful treatment was significantly
associated with improved outcomes in both patients
with overt episodes and those with subtle episodes,
although it is not clear whether the success of treat-
ment was the cause or the effect of the better prog-
nosis, or a combination of both.
Because even the best treatments were successful
in only about two thirds of the patients with overt
status epilepticus and one fourth of the patients with
subtle status epilepticus, our study underscores the
need for better methods of treating generalized con-
vulsive status epilepticus and its underlying causes.
Until new therapies become available, however, we
recommend lorazepam for the initial intravenous
treatment of generalized convulsive status epilepti-
cus. Although lorazepam was no more efficacious
than phenobarbital or than diazepam and phenyto-
in, it is easier to use.
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APPENDIX
Additional study participants included other investigators at the study
sites: S.D. Collins, S. Dane, S.L. Fish, D.A. Hosford, R.I. Kuzniecky, M.
Muxfeldt, H. Price, D. Rosenbaum, M.P. Remler, R.L. Ruff, P.A. Rutecki,
M.V. Sowa, M.L. Tomyanovich, and B.J. Wilder; the study coordinators:
D. Correll, A. Cugley, P. Encomienda, B. Gallo, K. Hall-Behrman, V.
Hamilton, E. Hwang, P. Jarres, A. Mann, J. McWhorter, D. Meija, C. Mix-
on, M. Moroney, D. Mueller, R. Nemire, K. Ohara, R. Palovcik, R. Reed,
M. Shove, L. Tuchman, L. Williams, and H.L. Yoon; staff of the study
chairman’s office: J. Bejaune, K. Fagan, and C. Stone; staff at the Veterans
Affairs Cooperative Studies Program Coordinating Center: B. Calvert, R.
Horney, D. Preston, and M. Rhoads; staff at the Veterans Affairs Cooper-
ative Studies Program Clinical Research Pharmacy Coordinating Center: J.
Peterson; and the staff of the central laboratory: E. Esteban, S. Gunawan,
Q. Jiang, and V. Pham.
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